157 related articles for article (PubMed ID: 26310246)
1. Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity.
Wu Y; Deng Z; Tang Y; Zhang S; Zhang YQ
BMC Cancer; 2015 Aug; 15():603. PubMed ID: 26310246
[TBL] [Abstract][Full Text] [Related]
2. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
3. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
Kobold S; Steffen J; Chaloupka M; Grassmann S; Henkel J; Castoldi R; Zeng Y; Chmielewski M; Schmollinger JC; Schnurr M; Rothenfußer S; Schendel DJ; Abken H; Sustmann C; Niederfellner G; Klein C; Bourquin C; Endres S
J Natl Cancer Inst; 2015 Jan; 107(1):364. PubMed ID: 25424197
[TBL] [Abstract][Full Text] [Related]
4. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.
Sun J; Dotti G; Huye LE; Foster AE; Savoldo B; Gramatges MM; Spencer DM; Rooney CM
Mol Ther; 2010 Nov; 18(11):2006-17. PubMed ID: 20842106
[TBL] [Abstract][Full Text] [Related]
5. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
6. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
Thanarajasingam U; Sanz L; Diaz R; Qiao J; Sanchez-Perez L; Kottke T; Thompson J; Chester J; Vile RG
Cancer Res; 2007 Jan; 67(1):300-8. PubMed ID: 17210711
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
Tähtinen S; Grönberg-Vähä-Koskela S; Lumen D; Merisalo-Soikkeli M; Siurala M; Airaksinen AJ; Vähä-Koskela M; Hemminki A
Cancer Immunol Res; 2015 Aug; 3(8):915-25. PubMed ID: 25977260
[TBL] [Abstract][Full Text] [Related]
8. A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiation.
Blaudszun AR; Moldenhauer G; Schneider M; Philippi A
J Control Release; 2015 Jan; 197():58-68. PubMed ID: 25449805
[TBL] [Abstract][Full Text] [Related]
9. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.
Galvan DL; O'Neil RT; Foster AE; Huye L; Bear A; Rooney CM; Wilson MH
PLoS One; 2015; 10(10):e0140744. PubMed ID: 26473608
[TBL] [Abstract][Full Text] [Related]
10. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.
Daly T; Royal RE; Kershaw MH; Treisman J; Wang G; Li W; Herlyn D; Eshhar Z; Hwu P
Cancer Gene Ther; 2000 Feb; 7(2):284-91. PubMed ID: 10770638
[TBL] [Abstract][Full Text] [Related]
11. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
12. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors.
Ren-Heidenreich L; Hayman GT; Trevor KT
Hum Gene Ther; 2000 Jan; 11(1):9-19. PubMed ID: 10646635
[TBL] [Abstract][Full Text] [Related]
13. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
14. Exuberated numbers of tumor-specific T cells result in tumor escape.
Goldberger O; Volovitz I; Machlenkin A; Vadai E; Tzehoval E; Eisenbach L
Cancer Res; 2008 May; 68(9):3450-7. PubMed ID: 18451173
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 overexpression enhances tumor-specific T-cell survival.
Charo J; Finkelstein SE; Grewal N; Restifo NP; Robbins PF; Rosenberg SA
Cancer Res; 2005 Mar; 65(5):2001-8. PubMed ID: 15753400
[TBL] [Abstract][Full Text] [Related]
17. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
Kalbasi A; Shrimali RK; Chinnasamy D; Rosenberg SA
J Immunother; 2010 Sep; 33(7):672-83. PubMed ID: 20664359
[TBL] [Abstract][Full Text] [Related]
18. Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.
Kobold S; Grassmann S; Chaloupka M; Lampert C; Wenk S; Kraus F; Rapp M; Düwell P; Zeng Y; Schmollinger JC; Schnurr M; Endres S; Rothenfußer S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26105028
[TBL] [Abstract][Full Text] [Related]
19. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
20. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]